Answers are grounded in this paper and cite their sources.
Accurate survival estimation fundamentally guides treatment strategy for metastatic bone disease, balancing durable surgical reconstruction against palliative care. Over three decades, predictive tools have evolved from static classical scores into sophisticated nomograms and machine learning algorithms, integrating patient reserve, tumor biology, metastatic burden, and treatment context. In this comprehensive review, we systematically searched PubMed, Embase, and Web of Science and identified 25 studies reporting the development or external validation of multivariable survival prediction models, encompassing classical scoring systems (Tokuhashi, Tomita, Bauer, Katagiri), nomograms (SORG), Bayesian networks (PATHFx), and machine learning algorithms (SORG‐MLA, BMETS). While this methodological evolution improved individualized prognostication in derivation cohorts, external validation studies reveal a critical disconnect: algorithmic complexity does not guarantee clinical transportability. Our synthesis identifies several recurrent sources of this transportability failure, primarily temporal calibration drift from evolving systemic therapies, anatomic site mismatches between spinal and appendicular disease, and selection biases inherent to surgical versus radiotherapeutic cohorts. Consequently, a substantial gap persists between methodological sophistication and actual bedside applicability, and routine clinical deployment of these tools remains premature until these foundational deficits are systematically addressed. Bridging this gap requires shifting from universal prediction tools toward context‐specific, prospectively validated models with routine temporal recalibration.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: